BioPharmSignal logoBioPharmSignal

Biotech News

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Oculis (OCS)OculisCompany update

Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to be presented by Baruch Kuppermann, M.D., Ph.D. New post-hoc analysis of OCT scans on GCIPL and analysis of responders with

Open original release

Related news

OCSOculis2026-05-05 08:00 EST

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

OCSOculis2026-04-20 08:00 EST

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

CLSDClearside Biomedical2025-05-09 11:05 EST

Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

VRDNViridian Therapeutics2021-09-30 12:06 EST

Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association

OCULOcular Therapeutix2026-02-23 12:00 EST

Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations

CLSDClearside Biomedical2025-07-17 11:05 EST

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

SGHTSight Sciences2026-04-29 20:05 EST

Sight Sciences to Present at Two Upcoming Investor Conferences

MGTXMeiraGTx2026-04-14 12:30 EST

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

OCULOcular Therapeutix2026-04-01 11:00 EST

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

MGTXMeiraGTx2025-11-10 12:00 EST

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

View all latest news

Oculis

Oculis is an eye-disease company focused on ophthalmology therapies and topical or local delivery approaches. Its strategy is to build a differentiated eye-care franchise in high-value indications.

Recent company news

OCSOculis2026-05-29 19:06 EST

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

OCSOculis2026-05-14 20:05 EST

Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors

OCSOculis2026-05-11 20:07 EST

Oculis Reports Q1 2026 Financial Results and Provides Company Update

OCSOculis2026-05-07 08:58 EST

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

OCSOculis2026-05-05 08:00 EST

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Stock data

Close
11.02 USD
Market cap
742.17M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States